IEFM
CRSP icon

IQ EQ Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

IQ EQ Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1M Buy
400,877
+11,358
+3% +$599K 1.45% 13
2025
Q4 		$20.4M Buy
389,519
+106,408
+38% +$6.37M 1.41% 14
2025
Q3 		$18.3M Buy
283,111
+87,509
+45% +$5.02M 1.24% 16
2025
Q2 		$9.51M Buy
195,602
+130,407
+200% +$5.05M 0.85% 26
2025
Q1 		$2.22M Buy
65,195
+28,931
+80% +$1.23M 0.26% 108
2024
Q4 		$1.43M Buy
36,264
+22,647
+166% +$1.07M 0.17% 140
2024
Q3 		$640K Buy
13,617
+4,909
+56% +$249K 0.07% 247
2024
Q2 		$470K Buy
+8,708
New +$504K 0.05% 255

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IQ EQ Fund Management's CRSP Position: Q1 2026 in Review

IQ EQ Fund Management increased its CRISPR Therapeutics (CRSP) stake by 2.9% in Q1 2026, buying an estimated $599K and bringing the position to 400,877 shares worth $19.1M. The position accounts for 1.45% of the portfolio, ranked #13.

IQ EQ Fund Management first reported a position in CRSP in Q2 2024 and has held it in 8 quarters since. The position peaked at $20.4M in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • IQ EQ Fund Management held 400,877 shares of CRISPR Therapeutics worth $19.1M as of Q1 2026.
  • IQ EQ Fund Management bought 11,358 CRISPR Therapeutics shares in Q1 2026, an estimated $599K.
  • CRISPR Therapeutics made up 1.45% of IQ EQ Fund Management's portfolio in Q1 2026, its #13 holding.
  • IQ EQ Fund Management first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • IQ EQ Fund Management's CRISPR Therapeutics position peaked at $20.4M in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on IQ EQ Fund Management's 13F filing for Q1 2026, filed 11 May 2026.